Future options for ALK-positive non-small cell lung cancer
作者： Daniela Iacono , Rita Chiari , Giulio Metro , Chiara Bennati , Guido Bellezza
DOI: 10.1016/J.LUNGCAN.2014.12.017
关键词: Anaplastic lymphoma kinase 、 Medicine 、 Ceritinib 、 Crizotinib 、 Targeted therapy 、 Cancer research 、 Lung cancer 、 Cancer 、 Gene rearrangement 、 Immunology 、 Alectinib
摘要: … , the treatment landscape of ALK-positive NSCLC is … knowledge of ALK-positive advanced non-small cell lung cancer. Also, … the ALK-TK, in an attempt to delineate how treatment of ALK-…
unipg.it
elsevier.com
sci-hub.se 参考文章(71)
D. Kim, M. Ahn, P. Yang, X. Liu, T. De Pas, L. Crinò, S. Lanzalone, A. Polli, A. Shaw, Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) Annals of Oncology. ,vol. 23, pp. 402- 402 ,(2012) , 10.1016/S0923-7534(20)33871-0
Conor E. Steuer, Suresh S. Ramalingam, ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options. Cancer. ,vol. 120, pp. 2392- 2402 ,(2014) , 10.1002/CNCR.28597
Yan Xu, Hongyu Liu, Jun Chen, Qinghua Zhou, Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009 Thoracic Cancer. ,vol. 1, pp. 83- 86 ,(2010) , 10.1111/J.1759-7714.2010.00016.X
Andrew J. Weickhardt, Dara L. Aisner, Wilbur A. Franklin, Marileila Varella-Garcia, Robert C. Doebele, D. Ross Camidge, Diagnostic assays for identification of anaplastic lymphoma kinase-positive non–small cell lung cancer Cancer. ,vol. 119, pp. 1467- 1477 ,(2013) , 10.1002/CNCR.27913
Eiko Theodora Browning, Andrew James Weickhardt, D. Ross Camidge, Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer. Journal of Thoracic Oncology. ,vol. 8, ,(2013) , 10.1097/JTO.0B013E31827A892C
Lynette M. Sholl, Stanislawa Weremowicz, Stacy W. Gray, Kwok-Kin Wong, Lucian R. Chirieac, Neal I. Lindeman, Jason L. Hornick, Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Journal of Thoracic Oncology. ,vol. 8, pp. 322- 328 ,(2013) , 10.1097/JTO.0B013E31827DB604
Norihiro Yamaguchi, Antonio R. Lucena-Araujo, Sohei Nakayama, Lorena L. de Figueiredo-Pontes, David A. Gonzalez, Hiroyuki Yasuda, Susumu Kobayashi, Daniel B. Costa, Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer. ,vol. 83, pp. 37- 43 ,(2014) , 10.1016/J.LUNGCAN.2013.09.019
Soyeon Kim, Tae Min Kim, Dong-Wan Kim, Heounjeong Go, Bhumsuk Keam, Se-Hoon Lee, Ja-Lok Ku, Doo Hyun Chung, Dae Seog Heo, None, Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer Journal of Thoracic Oncology. ,vol. 8, pp. 415- 422 ,(2013) , 10.1097/JTO.0B013E318283DCC0
Alice T. Shaw, Dong-Wan Kim, Ranee Mehra, Daniel S.W. Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J. Riely, Benjamin J. Solomon, Juergen Wolf, Michael Thomas, Martin Schuler, Geoffrey Liu, Armando Santoro, Yvonne Y. Lau, Meredith Goldwasser, Anthony L. Boral, Jeffrey A. Engelman, Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 370, pp. 1189- 1197 ,(2014) , 10.1056/NEJMOA1311107
Nir Peled, Gary Palmer, Fred R. Hirsch, Murry W. Wynes, Maya Ilouze, Marileila Varella-Garcia, Lior Soussan-Gutman, Geoff A. Otto, Philip J. Stephens, Jeffrey S. Ross, Maureen T. Cronin, Doron Lipson, Vincent A. Miller, Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 7, pp. e14- e16 ,(2012) , 10.1097/JTO.0B013E3182614AB5